Osmolyte-Enhanced CSF Drug Delivery to Brain Parenchyma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering proteins and gene therapy vectors to the central nervous system (CNS) face significant barriers, particularly the diffusion limitations in the cerebrospinal fluid (CSF) that restrict the distribution of macromolecules to only superficial brain and spinal cord regions, limiting their therapeutic effectiveness.
Innovation Solution
Introducing an osmolyte, such as mannitol or sorbitol, into the cerebrospinal fluid at specific concentrations to facilitate the access of therapeutic agents to the perivascular space within the CNS, enhancing their delivery and distribution through convection within the perivascular spaces of cerebral blood vessels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If drugs are delivered into the cerebrospinal fluid (CSF), then targeted CNS drug delivery with high brain and CSF levels is achieved, but diffusion limitations restrict distribution to only superficial brain and spinal cord regions
Solution Approach 1:
The patent changes the physical-chemical parameters of the CSF by introducing osmolytes (mannitol, sorbitol, glycerol) at specific concentrations (0.2-2.0 M) to alter the osmotic pressure and facilitate convective transport of macromolecules into the perivascular space and brain parenchyma, overcoming diffusion limitations
Solution Approach 2:
The patent uses osmolytes as intermediary substances that mediate between the CSF and brain tissue by creating osmotic gradients that drive convective flow, enabling enhanced transport of therapeutic agents without directly acting on the drug molecules themselves
2Reliability
If macromolecules are administered into the CSF, then high brain and CSF levels are achieved, but access to deeper brain and spinal cord areas is limited
Solution Approach 1:
The patent applies hydraulic principles by utilizing osmotic pressure gradients to drive convective flow of macromolecules through the perivascular space and into the brain parenchyma, replacing passive diffusion with active osmotically-driven transport to achieve deeper penetration
3Productivity
If conventional diffusion-based delivery is used, then simple administration is maintained, but widespread CNS transport is not achieved
Solution Approach 1:
The patent modifies the CSF composition by adding osmolytes at controlled concentrations to change the osmotic pressure parameter, thereby enhancing convective transport efficiency without requiring complex delivery devices or invasive procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the access of therapeutic agents to deeper brain and spinal cord areas, achieving more widespread CNS transport and potentially improving the treatment of various CNS diseases by enhancing the delivery of biologics and other large hydrophilic therapeutics.
Implementation Method 1
Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
Implementation Method 2
enhancing their delivery and distribution through convection within the perivascular spaces of cerebral blood vessels
Data Source
AI summary
A method of enhancing therapeutic/drug transport to the perivascular space of the brain of a patient is disclosed. In one embodiment, the method comprises the step of introducing a therapeutic/drug and an osmolyte of the present invention into a patient's cerebrospinal fluid (CSF), wherein the osmolyte is introduced to the CSF at a concentration of between 0.5 and 12.9 M (dependent on the solubility upper limit of the osmolyte), and wherein the therapeutic/drug delivery to the perivascular spaces of cerebral blood vessels and parenchyma of the central nervous system is facilitated by the presence of the osmolyte.